Introduction
With a prevalence of up to 35 %, the number of cases of female stress urinary incontinence
requiring operative treatment has risen drastically in recent years. On the one hand,
there is growing public awareness of the problem, with increasing freedom from taboos,
and increasing willingness of the affected women to undergo therapy. On the other
hand, newer operative techniques and materials with a trend towards minimally invasive
methods have been developed over the past 15 years.
The successful application of synthetic, tension-free vaginal slings with punctum
maximum in midurethra, an implementation of the integral theory of Ulmstem and Papa
Petros, has been confirmed in several studies with LoE I and II. Since 1995, more
than five million tapes have been implanted around the world, making this the most
frequently performed of all incontinence operations. In the meantime, over 16 years,
there have been numerous modifications to one of the materials and the insertion aids,
and differing sub-urethral access paths for insertion have been developed.
In respect to the material, there is a clear consensus: the tapes used are of polypropylene
material, type I in accordance with the amide classification of 1994. This monofilamentous
and macroporous material has a pore size > 75 µg and is characterised by fewer reactions
from foreign bodies and infections. Rejection reactions and persistent infections
can therefore be practically disregarded.
We Differentiate between Different Access Paths:
1. Retro-pubic route
First described in 1996 by Ulmsten, the retro-pubic route was the original passage
for tension-free tapes according to the currently existing conventional sling method.
The retro-pubic approach with introduction of the tape via a small colpotomy in the
midpart of the urethra and in supra-symphysary design (bottom-top = TVT® plastic,
Gynecare) has been used the longest and has the most study results. Current data from
2008, with a follow-up time of 11.5 years, confirm the high efficiency of the method,
with an objective continence rate of 90 %, a subjective continence rate of 77 % and
an improvement of 20 % (LoE II) [1]. According to a Cochrane analysis, the retro-pubic route with needle guided from
the abdomen to the vagina (top-bottom, e.g. Sparc®, AMS) shows a poorer continence
rate compared with the TVT® (77 vs. 82 %).
A number of studies comparing TVT and other incontinence operations exist. Burch colpo-suspensions
and retro-pubic slings give equally good success rates in respect to continence and
negligible side effects, even after five years, LoE I [2].
The retro-pubic passage entails risks and side effects; here, for example, one can
mention bladder lesion rates of 3–4 % and possible lesions affecting the intestine,
blood vessels or nerves on the pelvic wall. Overall, large national complication registers,
such as the Finnish register of Kuuva (2002) [3] or the Austrian register of Tamussino (2001) [4], show negligible and acceptable side effects. However, they also report severe problems,
including death.
2. Trans-obturator approach
The trans-obturator route introduced by Delorme in 2001 avoids the retro-pubic path
and passes the obturator fossa on both sides, but also requires a distinct blind passage.
In a comparison by Latthe et al. between retro-pubic and trans-obturator routes in
2007, no significant differences were found in terms of the continence rate; however,
significant differences were found in the examination of the side effects and complications.
In the TVT group, there were more bladder lesions and micturition disturbances due
to obstruction. At the same time, the trans-obturator method resulted in significantly
more vaginal erosions and pain syndromes, with dyspareunia and trouble bending the
legs [5].
A recent comparison by Latthe at al. of the trans-obturator method with the TVT-O®
(Gynecare) as an inside-out (introduction from the vagina to the abdomen) or Monarc®
(AMS) as an outside-in (introduction from outside and leading towards the vagina)
reported similar success rates, but indicated differences in terms of side effects
and complications. With the inside-out method, there were fewer bladder lesions and
fewer micturition disturbances, but more pain syndromes. With the outside-in method,
there were significantly more vaginal sulcus injuries [6].
3. Single-incision slings = mini-slings (SIS)
Since the end of the 1990s, developments have also taken place concerning the use
of the first mini-slings, which showed still less invasiveness due to a singular access.
With these new systems, blind passage is vastly reduced; that is, the tape is not
blindly inserted retro-pubically or via the obturator foramen. At the same time, this
utilises a considerably shorter sling of around 6.5–12 cm, thereby introducing less
foreign material. The objective is to achieve adequate continence rates compared with
the established sling methods, with a further significant reduction of possible complications.
[Table 1] lists the single-incision slings available on the market together with their specific
properties.
Table 1 List of the available single-incision slings.
|
Tape
|
Manufacturer
|
Material
|
Length
|
Insertion aid
|
Attachment
|
Adjustability
|
|
DynaMesh® minor
|
FEG Textiltechnik mbH, Aachen, Germany
|
PVDF monofilament
|
6 cm
|
no
|
self-adhesive surface
|
no
|
|
TFS®-System
|
TFS Surgical, Adelaide, Australia
|
Polypropylene monofilament
|
variable
|
yes
|
anchors
|
yes
|
|
Solyx®
|
Boston Scientific, Natick, MA, USA
|
Polypropylene monofilament
|
9 cm
|
yes
|
barbs
|
no
|
|
Minitape®
|
Gyneldas, Glasgow, UK
|
Polypropylene monofilament
|
14 cm
|
yes
|
anchors
|
no
|
|
Contasure Needleless®
|
Neomedic Int., Barcelona, Spain
|
Polypropylene monofilament
|
11.4 cm
|
no clamp
|
self-adhesive pocket system
|
no
|
|
TVT-secur®
|
Gynecare/Ethicon, Somerville, NJ, USA
|
Polypropylene monofilament
|
8 cm
|
yes
|
vicryl and PDS anchor tips
|
no
|
|
MiniArc-Precise®
|
AMS, Minnetonka, MN, USA
|
Polypropylene monofilament
|
8.5 cm
|
yes
|
anchors
|
no
|
|
Ajust®
|
C. R. Bard Inc., Murray Hill, NJ, USA
|
Polypropylene monofilament
|
6.5 cm
|
yes
|
anchors
|
yes
|
|
Ophira®
|
Promedon, Cordoba, Argentina
|
Polypropylene monofilament
|
3.8 cm mesh
|
yes
|
barbs
|
no
|
Initially, different tapes were used, including bio-materials with non-ready-to-use
insertion aids. For this reason, the classification of the initial data is very difficult
today.
In 1999, Palma et al. introduced the tendinous urethral support System (TUS system),
using a sub-urethral sling of bio-material. A bovine pericardium mini-sling was inserted
vaginally in 10 patients and anchored on both sides to the tendinous arch. Following
an initially high success rate after four weeks, distinct infections and erosions,
with an incontinence rate of 50 %, were found after one year [7]. In a subsequent trial, a porcine sling made from small bowel sub-mucosa was used.
Here again, initially there were high continence rates; initial results after six
months with 25 patients indicated a good continence rate of 87 %, dropping to 65 %
after 72 months [8], [9]. With the use of synthetic tape material, Palma was able to achieve a success rate
of 88 % and an improvement of 5.5 in 20 women in 2005 [10].
Since 2005, commercial systems with pre-fabricated slings and standardised insertion
aids have been available on the market. [Table 2] summarises the study results from this time onwards.
Table 2 List of the different studies on the use of single-incision slings (SIS) with success
rates and complication rates.
|
Author
|
Year
|
System
|
Study
|
Number
|
Follow-up
|
Success rate
|
Complications
|
|
U: U-position; H: H-position (Hammock); RH: residual urine
|
|
Palma [7]
|
1999
|
TUS
|
prospective
|
10
|
12 months
|
50 %
|
n = 2 removing tape due to infection n = 3 tape extrusion
|
|
Palma [8]
|
2001
|
TUS
|
retrospective
|
25
|
6 months
|
87 %
|
|
|
Palma [9]
|
2007
|
|
|
|
72 months
|
65 %
|
|
|
Petros [11]
|
2005
|
TFS
|
retrospective
|
36
|
9 months
|
83.4 %
|
n = 1 granuloma due to incorrect attachment
|
|
Petros [12]
|
2009
|
TFS
|
retrospective
|
31
|
36 months
|
80 % 6.5 % improvement
|
telephone survey 31 of 36 from [11]
|
|
Sivaslioglu [13]
|
2009
|
TFS
|
randomised clinical trial
|
39
|
36 months
|
90 %
|
n = 1 incorrect attachment
|
|
TOT
|
38
|
84 %
|
n = 2 residual urine
|
|
n = 12 groin pain
|
|
Debodinance [14]
|
2009
|
TVT-S®
|
prospective
|
154
|
12 months
|
70.3 % continence
|
n = 5 haemorrhaging
|
|
11 % improvement
|
n = 1 bladder lesion
|
|
n = 21 residual urine > 100 ml
|
|
n = 2 unattached tape
|
|
n = 7 injury to the vaginal sulcus
|
|
Lee [15]
|
2010
|
TVT-S®
|
prospective
|
144 U
|
12 months
|
87.5 %
|
n = 2 residual urine formation
|
|
141 H
|
12 months
|
80.1 %
|
n = 3 residual urine formation
|
|
n = 3 injury to the vaginal sulcus
|
|
n = 2 haemorrhaging > 500 ml
|
|
Liapsis [16]
|
2010
|
TVT-S®
|
prospective
|
39 U
|
12 months
|
71.8 % obj. cont.
|
|
|
43 H
|
12 months
|
62.8 % obj. cont.
|
|
|
Tommaselli [17]
|
2010
|
TVT-S®
|
prospective
|
37
|
12 months
|
83.8 %
|
n = 1 tape erosion
|
|
TVT-O®
|
|
38
|
12 months
|
81.6 %
|
n = 3 leg pain; n = 2 residual urine
|
|
Cornu [18]
|
2010
|
TVT-S®
|
prospective
|
45
|
1 month
|
62.2 %
|
n = 10 post-operative pain
|
|
6 months
|
53.3 %
|
n = 5 de novo urgency
|
|
30.8 months
|
40 %
|
|
|
Khandwala [19]
|
2010
|
TVT-S®
|
retrospective
|
141
|
14.1 months
|
83.0 % subj. cont.
|
n = 5 unattached tape
|
|
Oliveira [20]
|
2011
|
TVT-S®
|
prospective
|
30
|
12 months
|
67 %
|
n = 3 de novo urgency
|
|
TVT-O®
|
|
30
|
|
83 %
|
n = 3 de novo urgency, n = 2 split tape n = 2 groin pain
|
|
MiniArc®
|
30
|
|
87 %
|
n = 3 de novo urgency
|
|
|
|
n = 1 groin pain
|
|
Oliveira [21]
|
2011
|
TVT-S®
|
prospective
|
25
|
24 months
|
63 %; 13 % improvement
|
|
|
TVT-O®
|
|
24
|
|
82 %; 7 % improvement
|
|
|
MiniArc®
|
|
25
|
|
87 %; 7 % improvement
|
|
|
Tincello [22]
|
2010
|
TVT-S®
|
prospective
|
676
|
12 months
|
81.4 % subj. 84.8 % obj.
|
n = 1 bladder lesion n = 4 haemorrhaging > 500 ml n = 2 residual urine formation n = 16 de novo urgency
|
|
Han [23]
|
2010
|
TVT-S®
|
prospective
|
94
|
6 months
|
89.4 %
|
n = 1 bladder lesion
|
|
77
|
12 months
|
88.3 %
|
n = 3 vaginal perforation
|
|
23
|
24 months
|
82.6 %
|
n = 2 tape extrusion
|
|
Walsh [24]
|
2011
|
TVT-S®
|
review
|
1 178
|
12 months
|
76 % subj. 76 % obj.
|
1.5 % vaginal perforation 2.4 % tape erosion 10 % de novo urgency 2.3 % micturition disturbances
|
|
Kennelly [25]
|
2010
|
MiniArc®
|
prospective
|
188
|
12 months
|
90.6 %
|
n = 3 injury to the vaginal sulcus n = 5 de novo urgency n = 6 pain n = 4 dyspareunia
|
|
Kenelly [26]
|
2011
|
MiniArc®
|
prospective
|
142
|
24 months
|
85 %
|
|
|
De Ridder [27]
|
2010
|
MiniArc®
|
retrospective
|
75
|
12 months
|
85 %
|
n = 3 groin pain n = 5 de novo urgency
|
|
Monarc®
|
56
|
|
89 %
|
n = 1 haemorrhaging > 500 ml
|
|
|
|
n = 1 erosion
|
|
|
|
n = 2 groin pain
|
|
|
|
n = 8 de novo urgency
|
|
Enzelsberger [28]
|
2010
|
MiniArc®
|
prospective
|
45
|
24 months
|
82 %
|
n = 1 erosion n = 2 de novo urgency
|
|
Monarc®
|
|
45
|
|
86 %
|
n = 1 erosion n = 2 de novo urgency n = 1 required therapy for haematoma n = 11 groin pain
|
|
Oliveira [29]
|
2011
|
MiniArc®
|
prospective
|
105
|
12 months
|
80 %, 11 % improvement
|
n = 7 de novo urgency
|
|
Pickens [30]
|
2011
|
MiniArc®
|
prospective
|
120
|
12 months
|
94 %
|
n = 3 bladder lesions n = 1 tape loosening n = 5 de novo urgency
|
|
Pickens [31]
|
2011
|
MiniArc®
|
prospective
|
108
|
24 months
|
93 %
|
n = 5 de novo urgency
|
|
Naumann [32]
|
2010
|
Ajust®
|
prospective
|
52
|
12 months
|
86.5 %
|
n = 1 intra-operative new tape n = 1 14 days post-operative new tape
|
|
Naumann [33]
|
2011
|
Ajust®
|
prospective
|
51
|
24 months
|
82.4 % 4 % improvement
|
n = 4 no follow-up no complications
|
|
Meschia [34]
|
2011
|
Ajust®
|
prospective
|
111
|
6 months
|
91.4 % obj. cont.
|
n = 6 intra-operative new tape n = 1 tape cutting due to residual urine n = 9 de novo urgency
|
|
Abdel-Fattah [35]
|
2011
|
Ajust®
|
prospective
|
90
|
12 months
|
80 % subj. cont. 6 % improvement
|
n = 1 intra-operative new tape n = 2 tape erosion
|
|
Palma [10]
|
2008
|
Ophira®
|
retrospective
|
20
|
12 months
|
88 %
|
none
|
|
Palma [36]
|
2010
|
Ophira®
|
prospective
|
91
|
12 months
|
90.2 %
|
n = 3 mesh exposure n = 1 tape loosening n = 1 tape cutting
|
|
Serels [39]
|
2010
|
Solyx®
|
retrospective
|
63
|
6.5 months
|
95 %
|
none
|
|
Tardiu [40]
|
2011
|
Contasure Needleless
|
prospective
|
72
|
12 months
|
87.5 %
|
n = 1 haemorrhaging > 500 ml n = 1 bladder lesion n = 1 post-operative pain n = 4 residual urine
|
|
TVT-O®
|
|
60
|
|
90 %
|
n = 1 bladder lesion n = 7 post-operative pain n = 3 residual urine
|
|
Navazo [41]
|
2009
|
Contasure Needleless
|
retrospective
|
120
|
24 months
|
84 % 8 % improvement
|
n = 1 sling extrusion
|
In 2005, Petros et al. [11] introduced the tissue fixation system (TFS), using a multi-filamentous polypropylene
mini-sling, which was fixed in the muscle tissue underneath the symphysis. In a follow-up
of nine months, a continence rate of 83.4 % was determined with 36 patients without
additional complications. A subsequent telephone survey three years later of 31 of
these women indicated a continence rate of 80 % and 6.5 % improvement. In a prospective,
randomised study by Sivaslioglu et al. (2009), the TFS system was compared with an
outside-in TOT sling. In a follow-up time of 36 months, the TFS group (n = 39) showed
a success rate of 90 %, compared with 84 % for the TOT group (n = 38). 12 women in
the TOT group (31.5 %) had distinct pain symptoms during inguinal extensor movements
[13]. Currently, there are no further relevant German publications or evidence of expansion
of this system in Germany.
Since 2006, a number of different ready-made systems with further simplification of
the tape system have been developed in order to encourage their widespread use. As
with the conventional tension-free slings, the Type I propylene material has gained
widespread acceptance. These systems are inserted into the vagina by a small colpotomy
and are generally guided and attached via both sides of the obturator internus muscular
fasciae in the obturator membrane directly, or less frequently, retro-pubically. This
attachment is implemented either by absorbable patches, such as TVT Secur® (Gynecare),
by a self-adhesive surface, such as DynaMesh SIS® minor (FEG Textiltechnik mbH), or
otherwise by mini-anchor systems, such as MiniArc Precise® (AMS), Ajust® (Bard) or
Ophira® (Promedon). With a tape length of around 6.5 to 8.5 cm, the blind passage
and accompanying possible complications are reduced to a minimum.
3.1. TVT Secur (Gynecare)
The TVT S system was the first widely used mini-sling system since 2006. A tape of
around 8 cm in length with absorbable patches at the end is fixed with a fine metal
lance to both sides in a U-form retro-pubically or in an H-form (hammock) trans-obturatorically
([Fig. 1]). A release mechanism frees the tape from the inserter. The initial clinical euphoria
with good success rates was followed by a sobering decline in its use. The reasons
were the poorer results in the long term and some problems with serious outcomes such
as distinct haemorrhaging.
Fig. 1 TVT Secur® sling (Gynecare).
An unsolved problem with all mini-sling systems is the method of applying tension
to the inserted tape. In the, up to now, entirely tension-free TVT insert, particularly
the TVT Secur showed considerably poorer results; a significant improvement in the
continence rate was observed only with the introduction of a less tension-free insertion
of the tape with contact to the urethra and without additional interspace.
The data available from the literature vary between 40 and 87 % [14], [15], [16], [17], [18], [19], [20]. Investigations in our own hospital showed a continence rate of 63 %, with 23 %
improvement. However, recent data from 2010 indicate overall high efficiency, with
continence rates of more than 80 % and negligible side effects. In 2010, Tincello
et al. introduced a TVT S global register with a total of 676 patients from 29 centres
and, in a 12 month follow-up, found an objective continence rate of 84.8 % with overall
minimal complications [22]. The data from Han et al. [23] from the first two years also show a good success rate of 82.6 %. A current review
by Walsh (2011) [24] evaluates 10 studies
with a total of 1178 patients and a minimum follow-up time of 12 months. The review
reports a subjective and objective continence rate of 76 %, with better results obtained
when employing an insert in a “U”-form. In Germany, there are no current publications.
3.2. MiniArc Precise® (AMS)
The MiniArc system utilises a distinctly smaller insertion aid. Here, the tape with
a length of around 8 cm is attached by two anchors, on both sides in the obturator
internus muscular fasciae. In a further development to the MiniArc Precise®, the tape
is fixed to the insertion needle by a special attachment mechanism and freed by a
special release mechanism ([Fig. 2]). This system can be comfortably inserted, shows only minimal side effects and is
particularly convincingly because it is practically pain free, which would also allow
insertion under local anaesthesia.
Fig. 2 MiniArc Precise® sling (American Medical Systems).
Current publications from 2010 and 2011 report that the method is highly efficient,
is without significant side effects, and has a success rate of 82–93 % [20], [21], [25], [26], [27], [28], [29], [30], [31]. Although this tape, due to the specific length and the defined attachment points,
cannot be subsequently adjusted, problems such as obstruction, residual urine formation
or urgency occur with the same negligible frequency as with the established slings.
Compared with the established trans-obturator method, the MiniArc Precise® shows the
same good success rates [20], [21], [27], [28].
In the meantime, the first study results of a two-year follow-up period have been
published. These results also indicate high success rates in the long-term (one-year
follow-up 84–93.5 % continence rate, two-year follow-up 82–93 % continence rate) [21], [26], [28], [31].
3.3. Ajust® (C. R. Bard Inc.)
In 2008, the Ajust® sling, another single-incision sling, was introduced. This system
is inserted with a special arcuate inserter and attached by a special anchor directly
to the membrane of the obturator foramen ([Fig. 3]). The special feature with this system is the direct, intra-operative bilateral
adjustability of the tape. The two anchors are placed and the tape is then loosened
and tightened as required on the basis of a mesh extension in order to adapt to the
optimal tape length for the individual.
Fig. 3 Ajust® sling (C. R. Bard).
The developers of this system were able to insert the first tape world-wide in 2008
and were able in 2009 to report on the data from the first 12 months, which showed
a good continence rate of 86.5 % and no complications. Continued observation after
24 months confirmed the high success rate, with results of 82 % [32], [33]. Meschia et al. [34] again confirm these results in a prospective study with a follow-up time of six
months, reporting an objective continence rate of 91.4 %, and an on-going, 2011 prospective
study from Abdel-Fattah [35] indicates 80 % subjective continence after 12 months and the possibility of surgically
inserting under purely local anaesthesia.
3.4. Ophira® (Promedon)
The Ophira® mini-sling employs anchoring arms with numerous barbs. A thin insertion
aid positions the tape and can be disconnected without problems ([Fig. 4]).
Fig. 4 Ophira® sling (Promedon).
To date, there is a lack of publications with convincing data. In 2008, Palma et al.
published the first data with a success rate of 88 % after 12 months for 20 patients
[10]. A more recent prospective analysis of the same group of 91 women reports a continence
rate of 90.4 % without side effects after 12 months [36]].
In a first review published in 2010 [37], the data for n = 2734 TVT Secur®, n = 557 Miniarc® and n = 30 Ajust® were evaluated.
Success rates of 70–80 % were determined, which at the present time is slightly less
than rates for the established sling systems. The problem here is evidently the requirement
of a somewhat less tension-free insertion of the tapes, which only achieves full effectiveness
when the tape is in contact with the urethra. The analysis also included early studies
from this learning phase. At the same time, however, the complication rates were found
to be minimal; the bladder perforation rate was 0.45 % (compared with 3–4 % with the
TVT or TOT), with a de novo urgency of 6.6 % and 0.65 % for inguinal extensor complaints.
Another review from Abdel-Fattah in 2011 [38] summarising nine randomised clinical trial studies and comparing single-incision
slings with conventional slings (n = 548 TVT
Secur®, n = 160 MiniArc® and n = 50 Ophira®) confirms this trend. Here also, the success
rates of the single-incision slings were only slightly lower, with reduced side effects.
3.5. Other single-incision slings
Besides the mini-slings employed widely in Germany described here, there are also
other types of slings. The Solyx® system also utilises a small insertion aid and the
tape is fixed with barbs. Initial analyses indicate high success rates and no side
effects [39].
With the Contasure Needleless® system, the sling is attached with a clamp to both
sides by a pocket with a self-adhesive surface. Even without fixed attachment, the
results are also between 84 and 87 %, however bladder lesions and post-operative pain
were also reported [40], [41].
Practical Notes for the Use of Single-Incision Slings
The short-term and long-term data available to date for the new single-incision slings
allow us to assume that the success rates with these instruments is comparable with
those of established slings. At the same time, however, initial analysis underscores
the significantly reduced side effect rate and complication rate due to the lack of
a blind passage for fixation of the sling.
So far, retro-pubic and trans-obturator established slings have shown equivalent results
and, to the same extent, a negligible rate of various complications.
For certain indications, a specific access path is clearly favoured. In the presence
of intrinsic closure weakness of the urethra, the retro-pubic access path gives significantly
better results. For pre-operative interventions in the retro-pubic region, the trans-obturator
access path is clearly preferable.
In the opinion of the authors, single-incision slings will be able to replace trans-obturator
slings in the long term or sooner. With stable fixation, a tape passage in the obturator
foramen is then no longer necessary; therapy for the particular problems occurring
here, such as haemorrhaging, infection or nerve lesions, is very difficult.
Advantages of mini-incision slings
-
further dramatic reduction of possible complications
-
practically pain-free insertion of the tape, possible even under local anaesthesia
-
use of less foreign material
Possible indications for single-incision slings
-
operative correction for female stress urinary incontinence
-
avoids retro-pubic passage during pre-operative interventions
-
suitable for use with patients with a higher morbidity (e.g. adiposity, increased
risk of haemorrhaging, pre-operative vaginal interventions)
-
patients with mixed incontinence